COMPASS Pathways plc CMPS
Set alert
At close · Oct 30
After hours · Oct 30, 7:12 PM ET
- YTD
- +67.68%
- 1 year
- +83.65%
- Open
- 11.82
- Prev close
- 12.19
- Mkt cap
- 1.60B
- Vol
- 2.18M
- Avg vol
- 2.65M
- EPS
- -3.76
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 11.27
- High
- 11.99
- Forward P/E
- -8.07
- Beta
- 2.56
- Short ratio
- 6.40
- Inst. own
- 69.35%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 3, 2026
- 50-d avg
- 12.95
- 200-d avg
- 10.38
- 1y target
- 23.75
5D chart
Signals (108)
| Name | Time | Ago |
|---|---|---|
| RSI: Overbought | Oct 30, 3:50 PM | 1 day ago |
| SMA: Bullish | Oct 30, 2:55 PM | 1 day ago |
| SMA: Bearish | Oct 30, 2:45 PM | 1 day ago |
| SMA: Bullish | Oct 30, 2:40 PM | 1 day ago |
| SMA: Bearish | Oct 30, 2:10 PM | 1 day ago |
| RSI: Oversold | Oct 30, 12:50 PM | 1 day ago |
| SMA: Bearish | Oct 30, 12:45 PM | 1 day ago |
| MACD: Buy Signal | Oct 30, 12:30 PM | 1 day ago |
| SMA: Bullish | Oct 30, 12:25 PM | 1 day ago |
| RSI: Oversold | Oct 30, 11:55 AM | 1 day ago |
| RSI: Oversold | Oct 30, 11:45 AM | 1 day ago |
| MACD: Sell Signal | Oct 30, 11:40 AM | 1 day ago |
| SMA: Bearish | Oct 30, 11:20 AM | 1 day ago |
| MACD: Buy Signal | Oct 30, 10:45 AM | 1 day ago |
| SMA: Bullish | Oct 30, 10:35 AM | 1 day ago |
| RSI: Oversold | Oct 30, 10:15 AM | 1 day ago |
| RSI: Oversold | Oct 30, 9:45 AM | 1 day ago |
| SMA: Bearish | Oct 30, 9:30 AM | 1 day ago |
| SMA: Bearish | Oct 30, 9:30 AM | 1 day ago |
| MACD: Sell Signal | Oct 30, 9:30 AM | 1 day ago |
| RSI: Oversold | Oct 30, 9:30 AM | 1 day ago |
| MACD: Buy Signal | Oct 29, 2:40 PM | 2 days ago |
| SMA: Bullish | Oct 29, 2:35 PM | 2 days ago |
| MACD: Sell Signal | Oct 29, 1:50 PM | 2 days ago |
| SMA: Bearish | Oct 29, 1:10 PM | 2 days ago |
| SMA: Bullish | Oct 29, 12:55 PM | 2 days ago |
| MACD: Buy Signal | Oct 29, 12:55 PM | 2 days ago |
| SMA: Bearish | Oct 29, 12:50 PM | 2 days ago |
| SMA: Bearish | Oct 29, 12:30 PM | 2 days ago |
| SMA: Bullish | Oct 29, 12:20 PM | 2 days ago |
| SMA: Bearish | Oct 29, 11:15 AM | 2 days ago |
| SMA: Bullish | Oct 29, 11:00 AM | 2 days ago |
| SMA: Bearish | Oct 29, 10:55 AM | 2 days ago |
| SMA: Bearish | Oct 29, 10:45 AM | 2 days ago |
| MACD: Sell Signal | Oct 29, 10:40 AM | 2 days ago |
| SMA: Bullish | Oct 29, 10:10 AM | 2 days ago |
| SMA: Bearish | Oct 29, 10:05 AM | 2 days ago |
| RSI: Overbought | Oct 29, 10:00 AM | 2 days ago |
| RSI: Overbought | Oct 28, 3:45 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 3:25 PM | 3 days ago |
| SMA: Bullish | Oct 28, 3:20 PM | 3 days ago |
| SMA: Bullish | Oct 28, 3:20 PM | 3 days ago |
| SMA: Bearish | Oct 28, 3:00 PM | 3 days ago |
| SMA: Bearish | Oct 28, 3:00 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 3:00 PM | 3 days ago |
| SMA: Bullish | Oct 28, 2:55 PM | 3 days ago |
| SMA: Bullish | Oct 28, 2:55 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 2:55 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 2:50 PM | 3 days ago |
| SMA: Bearish | Oct 28, 2:45 PM | 3 days ago |
| SMA: Bearish | Oct 28, 2:45 PM | 3 days ago |
| SMA: Bullish | Oct 28, 2:35 PM | 3 days ago |
| SMA: Bullish | Oct 28, 2:35 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 2:35 PM | 3 days ago |
| SMA: Bearish | Oct 28, 2:30 PM | 3 days ago |
| SMA: Bearish | Oct 28, 2:30 PM | 3 days ago |
| SMA: Bullish | Oct 28, 2:25 PM | 3 days ago |
| SMA: Bullish | Oct 28, 2:25 PM | 3 days ago |
| SMA: Bearish | Oct 28, 2:20 PM | 3 days ago |
| SMA: Bearish | Oct 28, 2:20 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 2:20 PM | 3 days ago |
| SMA: Bullish | Oct 28, 2:15 PM | 3 days ago |
| SMA: Bullish | Oct 28, 2:15 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 2:15 PM | 3 days ago |
| SMA: Bearish | Oct 28, 2:05 PM | 3 days ago |
| SMA: Bearish | Oct 28, 2:05 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 2:05 PM | 3 days ago |
| SMA: Bullish | Oct 28, 2:00 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 2:00 PM | 3 days ago |
| SMA: Bullish | Oct 28, 1:50 PM | 3 days ago |
| SMA: Bearish | Oct 28, 12:35 PM | 3 days ago |
| SMA: Bearish | Oct 28, 12:00 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 11:55 AM | 3 days ago |
| RSI: Overbought | Oct 28, 11:20 AM | 3 days ago |
| MACD: Buy Signal | Oct 27, 3:50 PM | 4 days ago |
| MACD: Sell Signal | Oct 27, 3:45 PM | 4 days ago |
| SMA: Bullish | Oct 27, 3:40 PM | 4 days ago |
| MACD: Buy Signal | Oct 27, 3:40 PM | 4 days ago |
| MACD: Sell Signal | Oct 27, 3:35 PM | 4 days ago |
| MACD: Buy Signal | Oct 27, 2:40 PM | 4 days ago |
| SMA: Bearish | Oct 27, 1:35 PM | 4 days ago |
| SMA: Bearish | Oct 27, 1:35 PM | 4 days ago |
| SMA: Bearish | Oct 27, 12:30 PM | 4 days ago |
| RSI: Overbought | Oct 27, 12:20 PM | 4 days ago |
| MACD: Sell Signal | Oct 27, 12:15 PM | 4 days ago |
| RSI: Overbought | Oct 27, 11:15 AM | 4 days ago |
| RSI: Overbought | Oct 27, 10:35 AM | 4 days ago |
| RSI: Overbought | Oct 27, 10:25 AM | 4 days ago |
| SMA: Bullish | Oct 27, 9:50 AM | 4 days ago |
| SMA: Bearish | Oct 27, 9:45 AM | 4 days ago |
| SMA: Bullish | Oct 27, 9:35 AM | 4 days ago |
| MACD: Buy Signal | Oct 27, 9:35 AM | 4 days ago |
| SMA: Bearish | Oct 26, 3:50 PM | 5 days ago |
| MACD: Sell Signal | Oct 26, 3:50 PM | 5 days ago |
| MACD: Buy Signal | Oct 26, 3:35 PM | 5 days ago |
| SMA: Bullish | Oct 26, 3:30 PM | 5 days ago |
| RSI: Oversold | Oct 26, 3:00 PM | 5 days ago |
| SMA: Bearish | Oct 26, 2:25 PM | 5 days ago |
| MACD: Sell Signal | Oct 26, 2:25 PM | 5 days ago |
| MACD: Buy Signal | Oct 26, 2:15 PM | 5 days ago |
| SMA: Bullish | Oct 26, 1:55 PM | 5 days ago |
| SMA: Bearish | Oct 26, 1:25 PM | 5 days ago |
| SMA: Bullish | Oct 26, 1:15 PM | 5 days ago |
| MACD: Sell Signal | Oct 26, 12:45 PM | 5 days ago |
| SMA: Bearish | Oct 26, 12:40 PM | 5 days ago |
| SMA: Bearish | Oct 26, 11:50 AM | 5 days ago |
| SMA: Bullish | Oct 26, 11:00 AM | 5 days ago |
| SMA: Bearish | Oct 26, 10:25 AM | 5 days ago |
News
3 days ago businesswire.com
Compass Pathways to Highlight Scientific Research and TRD Disease State Education Efforts at the 2026 Neuroscience Education Institute Fall Congress
LONDON & JERSEY CITY, N.J.--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental…
4 days ago seekingalpha.com
Compass Pathways: A Compelling Opportunity In A Large And Underserved Market
COMPASS Pathways is currently engaged in a rolling submission and review with the FDA for COMP360 and expects a commercial launch in the first half of 2027. COMPASS is initially targeting the TRD…
4 days ago businesswire.com
Compass Pathways to Announce Third Quarter 2026 Financial Results on November 3, 2026
LONDON & JERSEY CITY, N.J.--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental…
1 week ago seekingalpha.com
Compass Pathways: Built The FDA's Way, Valued At 0.57x Spravato's Sales
COMPASS Pathways is rated Buy, with high risk, based on strong trial design and imminent FDA review for COMP360 in treatment-resistant depression. COMP360's Phase 3 trials matched FDA guidance,…
2 weeks ago businesswire.com
Compass Pathways Joins Forces with Leading Mental Health Organizations to Mark First-Ever U.S. Treatment-Resistant Depression (TRD) Awareness Day
LONDON & JERSEY CITY, N.J.--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental…
3 weeks ago benzinga.com
Compass Pathways Reports Q2 2026 Results: Full Earnings Call Transcript
Compass Pathways (NASDAQ:CMPS) released second-quarter financial results and hosted an earnings call on Wednesday. Read the complete transcript below. This content is powered by Benzinga APIs. For…
4 weeks ago businesswire.com
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care,…
1 month ago defenseworld.net
Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) Stock Has Consensus Target Price of $23.36 According to Brokerages
Compass Pathways PLC Sponsored ADR (NASDAQ: CMPS - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the seventeen brokerages that are currently covering the…
1 month ago businesswire.com
Compass Pathways Appoints Kelley Boucher as Chief People Officer
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care,…
1 month ago marketbeat.com
Compass Pathways Targets Q4 COMP360 NDA Completion, Eyes 2027 Launch
Compass Pathways NASDAQ: CMPS executives said the company remains on track to complete its rolling New Drug Application submission for COMP360 in the fourth quarter, while preparing commercial…
1 month ago defenseworld.net
Compass Pathways Eyes 2027 COMP360 Launch as FDA Review Advances
Compass Pathways (NASDAQ: CMPS) expects to complete its new drug application submission for COMP360, its investigational psilocybin treatment for treatment-resistant depression, in the fourth…
1 month ago marketbeat.com
Compass Pathways Targets 2027 COMP360 Launch After Positive Phase III Depression Data
Compass Pathways NASDAQ: CMPS said it remains on track to complete its rolling New Drug Application submission for COMP360 in the fourth quarter of 2026, following positive Phase III studies of its…
1 month ago marketbeat.com
Compass Pathways Eyes 2027 COMP360 Launch as FDA Review Advances
Compass Pathways NASDAQ: CMPS expects to complete its new drug application submission for COMP360, its investigational psilocybin treatment for treatment-resistant depression, in the fourth quarter,…
1 month ago marketbeat.com
Compass Pathways Eyes 2027 COMP360 Launch as FDA Filing Nears
Compass Pathways NASDAQ: CMPS said it expects to complete its rolling New Drug Application submission for its synthetic psilocybin treatment, COMP360, in the fourth quarter and continues to target a…
1 month ago seekingalpha.com
COMPASS Pathways plc (CMPS) Presents at Deutsche Bank 2026 Healthcare Summit Transcript
COMPASS Pathways plc (CMPS) Presents at Deutsche Bank 2026 Healthcare Summit Transcript
1 month ago seekingalpha.com
COMPASS Pathways plc (CMPS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
COMPASS Pathways plc (CMPS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
1 month ago businesswire.com
Compass Pathways to Participate in TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit on September 23, 2026
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care,…
1 month ago businesswire.com
Compass Pathways Launches ‘Change the Tune in TRD' in the U.S. to Advance HCP Understanding of Treatment-Resistant Depression at Psych Congress 2026
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care,…
1 month ago defenseworld.net
Engineers Gate Manager LP Has $2.43 Million Position in Compass Pathways PLC Sponsored ADR $CMPS
Engineers Gate Manager LP lessened its holdings in Compass Pathways PLC Sponsored ADR (NASDAQ: CMPS) by 21.1% during the undefined quarter, according to its most recent filing with the Securities and…
1 month ago businesswire.com
Strata Mental Health Solutions Awarded U.S. Healthcare Provider Training Grant from Compass Pathways to Develop Provider Training for COMP360
ATLANTA--(BUSINESS WIRE)--Strata Mental Health Solutions, the expert-led training and implementation partner preparing clinical networks to deliver psychedelic treatments, today announced it has been…
1 month ago prnewswire.com
Fluence Selected by Compass Pathways to Develop Post-Approval COMP360 Provider Training
New certificate program will prepare clinicians to support patients receiving COMP360 psilocybin treatment, if approved by the FDA NEW YORK, Sept. 10, 2026 /PRNewswire/ -- Fluence, a leading provider…
-
1 month ago benzinga.com
Compass Pathways Announces U.S. Healthcare Provider Grant Program Recipients To Create Training For Delivery Of Psychedelic Treatments
These programs are intended to address both the need for foundational training in psychedelics, as well as ensuring HCPs are well-prepared to care for patients receiving treatment with COMP360…
1 month ago benzinga.com
Compass Pathways’ Psilocybin Treatment Shows Lasting Benefits in Treatment-Resistant Depression
Compass Pathways surges 11% after COMP360 Phase 3 trial shows durable 52-week relief for treatment-resistant depression.
-
1 month ago benzinga.com
Compass Pathways Shares Topline 52-week Results (Part C) From Its Phase 3 COMP005 Trial Of Comp360 For Treatment-Resistant Depression, Showing Additional Benefit Extending Durability Out To 1 Year
Notable additional benefit observed with an added reduction in MADRS1 score leading to an average 13-point reduction from baseline at Week 52 with durability extended out to 1 year for participants…
-
1 month ago benzinga.com
'FDA’s Acting Drug, Vaccine Regulators Tapped for Permanent Roles'- Bloomberg
https://www.bloomberg.com/news/articles/2026-09-08/fda-s-acting-drug-vaccine-regulators-tapped-for-permanent-roles
-
1 month ago benzinga.com
Compass Pathways To Participate In Psych Congress 2026 With New Educational Campaign Regarding Treatment-Resistant Depression
Congress taking place in New Orleans, LA, from September 14-19. The Company will debut Change the Tune in TRD, a new educational campaign for U.S. HCPs focused on TRD, and present new HEOR data…
2 months ago benzinga.com
10 Health Care Stocks With Whale Alerts In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
-
2 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on Compass Pathways, Lowers Price Target to $65
HC Wainwright & Co. analyst Patrick R. Trucchio maintains Compass Pathways (NASDAQ:CMPS) with a Buy and lowers the price target from $70 to $65.
-
2 months ago benzinga.com
Morgan Stanley Maintains Overweight on Compass Pathways, Raises Price Target to $18
Morgan Stanley analyst Judah Frommer maintains Compass Pathways (NASDAQ:CMPS) with a Overweight and raises the price target from $17 to $18.
-
2 months ago benzinga.com
RBC Capital Maintains Outperform on Compass Pathways, Lowers Price Target to $21
RBC Capital analyst Leonid Timashev maintains Compass Pathways (NASDAQ:CMPS) with a Outperform and lowers the price target from $22 to $21.
-
2 months ago benzinga.com
B. Riley Securities Maintains Buy on Compass Pathways, Raises Price Target to $22
B. Riley Securities analyst Madison El-Saadi maintains Compass Pathways (NASDAQ:CMPS) with a Buy and raises the price target from $17 to $22.
-
2 months ago benzinga.com
Compass Pathways Collaborates With U.S. Department Of Veterans Affairs On A Multi-Site Randomized Controlled Clinical Trial
The study will evaluate the safety and efficacy of COMP360 psilocybin in the treatment of treatment-resistant depression (TRD) in veterans, including those with concurrent post-traumatic stress…
-
2 months ago benzinga.com
UPDATE: Compass Pathways Q2 Adj. EPS $(0.36) Beats $(0.40) Estimate. (Adj EPS excludes Fair value change of warrant liabilities)
Compass Pathways (NASDAQ:CMPS) reported quarterly losses of $(0.36) per share which beat the analyst consensus estimate of $(0.40) by 10 percent. This is a 12.2 percent increase over losses of…
-
2 months ago benzinga.com
Compass Pathways Q2 EPS $(1.88) Misses $(0.37) Estimate
Compass Pathways (NASDAQ:CMPS) reported quarterly losses of $(1.88) per share which missed the analyst consensus estimate of $(0.37) by 408.11 percent. This is a 358.54 percent decrease over losses…
-
3 months ago benzinga.com
Wells Fargo Initiates Coverage On Compass Pathways with Equal-Weight Rating, Announces Price Target of $13
Wells Fargo analyst Benjamin Burnett initiates coverage on Compass Pathways (NASDAQ:CMPS) with a Equal-Weight rating and announces Price Target of $13.
3 months ago benzinga.com
Why Is Robinhood Stock Falling on Thursday?
Robinhood Markets Inc. (NASDAQ: HOOD) stock declines on Thursday due to tech market pullbacks, recent ARK Invest portfolio shifts and upcoming Q2 earnings.
3 months ago benzinga.com
Cathie Wood Swaps Robinhood for SpaceX, Archer—Did ARK Pivot Back to Moonshot Innovation?
Cathie Wood sold $10M of Robinhood while adding $15M to SpaceX and boosting Archer Aviation. Here's what ARK Invest's ETF rotation signals.
3 months ago benzinga.com
Why Is Neuronetics Stock Soaring Monday?
BTIG initiates coverage on Neuronetics (STIM) with a Buy rating and $5 target as shares surge 28%. Read the details here.
3 months ago benzinga.com
Why Is GH Research Stock Trading Higher on Thursday?
GH Research and Definium Therapeutics stocks rose after Eli Lilly agreed to buy AtaiBeckley in a deal worth up to $3.8 billion.
-
3 months ago benzinga.com
Compass Pathways Announces Publication Of Post-Hoc Analysis Of Support Methods In Phase 2 Study Of Investigational COMP360 Synthetic Psilocybin Treatment
Post-hoc analysis of support methods used in an open-label Phase 2 COMP360 study showed monitoring and support provided during treatment administration sessions were minimal, non-directive and…
3 months ago benzinga.com
Why JB Hunt Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket
JB Hunt Transport Services Inc (JBHT) beat earnings and revenue estimates, causing shares to surge 7.9% in pre-market trading. Other top gainers include ATPC, TGHL, ATAI, DXST, KAPA, EHGO, HELP, VSA,…
-
3 months ago benzinga.com
6 Health Care Stocks With Whale Alerts In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
-
3 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Compass Pathways, Maintains $70 Price Target
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Compass Pathways (NASDAQ:CMPS) with a Buy and maintains $70 price target.
-
3 months ago benzinga.com
Evercore ISI Group Upgrades Compass Pathways to Outperform, Raises Price Target to $21
Evercore ISI Group analyst Gavin Clark-Gartner upgrades Compass Pathways (NASDAQ:CMPS) from In-Line to Outperform and raises the price target from $8 to $21.
-
3 months ago benzinga.com
Stifel Maintains Buy on Compass Pathways, Raises Price Target to $21
Stifel analyst Paul Matteis maintains Compass Pathways (NASDAQ:CMPS) with a Buy and raises the price target from $14 to $21.
-
3 months ago benzinga.com
Morgan Stanley Reiterates Overweight on Compass Pathways, Maintains $17 Price Target
Morgan Stanley analyst Judah Frommer reiterates Compass Pathways (NASDAQ:CMPS) with a Overweight and maintains $17 price target.
-
3 months ago benzinga.com
Oppenheimer Reiterates Outperform on Compass Pathways, Maintains $20 Price Target
Oppenheimer analyst Francois Brisebois reiterates Compass Pathways (NASDAQ:CMPS) with a Outperform and maintains $20 price target.
-
3 months ago benzinga.com
BTIG Maintains Buy on Compass Pathways, Raises Price Target to $25
BTIG analyst Thomas Shrader maintains Compass Pathways (NASDAQ:CMPS) with a Buy and raises the price target from $14 to $25.
3 months ago benzinga.com
Compass Pathways Highlights Long-Term Data from Resistant Depression, Backs 2027 Launch Timeline
Compass Pathways reported positive 26-week Phase 3 COMP360 data for treatment-resistant depression as its FDA filing remains on track.
-
3 months ago benzinga.com
Compass Pathways Announces 26-Week Results From Second Ongoing Phase 3 COMP006 Trial Of COMP360, Proprietary Formulation Of Psilocybin, For TRD Which Confirm COMP360’s Rapid Onset And Durable Profile
New 6-month data supports COMP360’s potential to establish a new standard of care in TRDData from positive COMP006 Phase 3 trial demonstrates durable benefit through at least 6 months further…